Skip to main content
Article thumbnail
Location of Repository

ACTIVITY OF TG01, A SELECTIVE COX-2 INHIBITOR, ALONE AND IN COMBINATION WITH STANDARD AGENTS IN HUMAN BREAST CARCINOMA XENOGRAFTS (Abstract # 5662)

By Sara L Zaknoen, Tracy L Lawhon, Andrew J Wong, Kathryn R Meshaw, Mary Ann Meade, Wr Leopold and All K Johnson

Abstract

The cyclooxygenase (COX) pathway has been implicated in carcinogenesis since the 1970s when increased concentrations of prostaglandins were detected in neoplastic tissues, especially colon cancer. Epidemiological studies have documented a decreased incidence of colorectal and breast cancer in patients taking non-specific COX inhibitors such as aspirin and non-steroidal anti-inflammatory drugs (NSAIDs). COX occurs in 2 isoforms: COX-1 is expressed constitutively in most tissues and is thought to serve a function in maintaining the integrity of the gastrointestinal (GI) tract and the renal medulla. COX-2 is in general not detectable in normal tissues and is upregulated in the presence of inflammation and neoplasia. COX-2 is consistently over expressed in a large percentage and variety of human tumors. The presence of elevated COX-2 in tumor tissue represents a poor prognostic factor in a number of tumors including breast cancer

Year: 2015
OAI identifier: oai:CiteSeerX.psu:10.1.1.629.7020
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.tragarapharma.com/a... (external link)
  • http://www.tragarapharma.com/a... (external link)
  • http://citeseerx.ist.psu.edu/v... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.